Is Merck & Co., Inc. (MRK) a Buy, Sell, or Hold?
Merck & Co., Inc.
NYSE:MRK
$120.8 USD
-$3.23 (-2.6%)
- Volume
- 9.08M
- Average Volume
- 10.4M
- Market Capitalization
- $298.35B
- P/E Ratio
- 33.93
- Dividend Yield
- 2.78%
- Price Target
- $142.00
- Year High
- $130.29
- Year Low
- $76.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.92
- Current Ratio
- $1.30
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Robert Davis |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | MRK |
| CUSIP | 58933Y105 |
| CIK | 0000310158 |
| Web | https://www.merck.com |
| Phone | 908 740 4000 |
| Currency | USD |
| Employees | 75000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.07 |
| Payout Ratio | 0.92 |
| Current Ratio | 1.30 |
| Quick Ratio | 1.06 |
| Cash Ratio | 0.20 |
Sales & Book Value
| Annual Sales | $64.93B |
| Price / Sales | 4.55 |
| Cash Flow | 5.71 |
| Price / Cash Flow | 21.14 |
| Price / Book | 6.51 |
Price Target and Rating
| Average Stock Price Forecast | $142.00 |
| High Stock Price Forecast | $155.00 |
| Low Stock Price Forecast | $100.00 |
| Forecast Upside/Downside | -14.93% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 37 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $7.28 |
| Trailing P/E Ratio | 33.93 |
| PEG Ratio | -0.70 |
| P/E Growth | -0.70 |
| Net Income | $18.25B |
| Net Margin | 13.62% |
| Pretax Margin | 17.73% |
| Return on Equity | 17.93% |
| Return on Assets | 6.94% |
Financials Score
| AltmanZ Score | 3.85 |
| Piotroski Score | 6.00 |
| Working Capital | 8.07B |
| Total Assets | 128.68B |
| Ebit | 12.67B |
| Market Cap | 305.12B |
| Total Liabilities | 82.75B |
Poll Results
About Merck & Co., Inc. (NYSE:MRK) Stock
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, ... and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
2026-07-13 12:11:04
Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.
Why Merck Stock Is in the Spotlight Today
2026-07-13 08:20:39
Merck & Co. Inc. (NYSE:MRK) shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
2026-07-10 18:46:03
In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
2026-07-10 14:10:00
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
2026-07-10 09:56:23
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
2026-07-09 10:01:04
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
2026-07-09 08:15:04
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
2026-07-08 09:26:06
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.
Frequently Asked Questions
-
What is the current Merck & Co., Inc. (MRK) stock price?
-
Merck & Co., Inc.(NYSE:MRK) stock price is $120.8 in the last trading session. During the trading session, MRK stock reached the peak price of $130.29 while $76.66 was the lowest point it dropped to. The percentage change in MRK stock occurred in the recent session was --2.6% while the dollar amount for the price change in MRK stock was -$-3.23.
-
MRK's industry and sector of operation?
-
The NYSE listed MRK is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of MRK?
-
Jennifer L. Zachary | Executive Vice President & General Counsel
Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications
Caroline Litchfield | Executive Vice President & Chief Financial Officer
Dean Y. Li | Executive Vice President & President of Merck Research Laboratories
David Michael Williams | Executive Vice President and Chief Information & Digital Officer -
How many employees does MRK have?
-
Number of MRK employees currently stands at 75000. MRK operates from 126 East Lincoln Avenue, Rahway, NJ 07065, US.
-
Link for MRK official website?
-
Official Website of MRK is: https://www.merck.com
-
How do I contact MRK?
-
MRK could be contacted at phone #908 740 4000 and can also be accessed through its website. MRK operates from 126 East Lincoln Avenue, Rahway, NJ 07065, US.
-
How many shares of MRK are traded daily?
-
The average number of MRK shares traded daily for last 3 months was 10.4M.
-
What is the market cap of MRK currently?
-
The market value of MRK currently stands at $298.35B with its latest stock price at $120.8